Cline Christopher R. 4
4 · Travere Therapeutics, Inc. · Filed Aug 28, 2025
Insider Transaction Report
Form 4
Cline Christopher R.
CHIEF FINANCIAL OFFICER
Transactions
- Sale
Common Stock
2025-08-27$17.31/sh−470$8,136→ 92,656 total
Footnotes (1)
- [F1]This sale was made pursuant to a written plan adopted on May 28, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of additional shares to cover the tax obligation that occurred upon the vesting of performance-based restricted stock units (PSUs) that vested in May 2025.